This summary was created by AI, based on 3 opinions in the last 12 months.
Royalty Pharma plc (RPRX-Q) has garnered attention from multiple analysts, all of whom identify it as a top pick in the pharmaceutical sector. The company operates uniquely by holding investments in jointly developed royalty products, allowing it to engage with major pharmaceutical firms. Analysts highlight its substantial returns on investments, such as a recent $230 million monetization yielding a 76% ROI, strengthening its financial position for debt repayment and product development. With appealing earnings multiples and a solid return on equity, the stock offers a good dividend yield, further supported by a low payout ratio. Experts suggest upward revisions for stop-loss levels and provide optimistic price targets, indicating a potential upside of around 25% while maintaining strong growth in their portfolio.
Royalty Pharma plc is a American stock, trading under the symbol RPRX-Q on the NASDAQ (RPRX). It is usually referred to as NASDAQ:RPRX or RPRX-Q
In the last year, there was no coverage of Royalty Pharma plc published on Stockchase.
Royalty Pharma plc was recommended as a Top Pick by on . Read the latest stock experts ratings for Royalty Pharma plc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Royalty Pharma plc In the last year. It is a trending stock that is worth watching.
On 2025-04-02, Royalty Pharma plc (RPRX-Q) stock closed at a price of $31.28.
We reiterate RPRX as a TOP PICK. This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development. It trades at 17x earnings, 2.1x book and supports a 12% ROE. We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%. Yield 2.6%
(Analysts’ price target is $41.00)